GlaxoSmithKline has filed a suit in a US District Court challenging the legal validity of its new rules that will be effective from the 1st of November, 2007. GlaxoSmithKline claims that USPTO does not have the legal authority to promulgate such rules. It further claims that the rules are vague and arbitrary. As per GlaxoSmithKline, the rules violate the rights of the inventor to get a patent and their retrospective effect makes the rules arbitrary. The court has issued a preliminary injunction restraining the implementation of the rules by USPTO until it decides the case on merits.

Transmeta filed a patent infringement suit against Intel claiming infringement of 10 of its patents and Intel responded by counter-claiming patent infringement of 7 of Intel's patents by Transmeta. The parties have now settled the dispute between them through a license agreement. Under the agreement, Transmeta has agreed to license its patent portfolio relating to computing, micro-processor and semi-conductor technologies to Intel for a lump sum royalty of 150 million dollars and a fixed royalty of 20 million dollars per year for the next five years. The agreement obligates Transmeta to license all its existing patents and patent applications filed by Transmeta during the next 10 years.